Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 221Carcinoma, Non-Small-Cell Lung 218Prostatic Neoplasms 150Multiple Myeloma 140Neoplasms 129Colorectal Neoplasms 117Leukemia, Myeloid, Acute 106Lung Neoplasms 102Neoplasm Metastasis 95Squamous Cell Carcinoma of Head and Neck 91Carcinoma, Hepatocellular 84Lymphoma 78Melanoma 77Triple Negative Breast Neoplasms 71Pancreatic Neoplasms 71Ovarian Neoplasms 66Sarcoma 64Lymphoma, Large B-Cell, Diffuse 61Carcinoma, Renal Cell 59Precursor Cell Lymphoblastic Leukemia-Lymphoma 57Head and Neck Neoplasms 57Recurrence 56Brain Neoplasms 56Lymphoma, Non-Hodgkin 53Hematologic Neoplasms 52Stomach Neoplasms 51Leukemia, Lymphocytic, Chronic, B-Cell 51Endometrial Neoplasms 50Small Cell Lung Carcinoma 48Rectal Neoplasms 46

Interventions

relacorilant 1ASP3662 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × ACTH Syndrome, Ectopic × 90 days × Clear all
NCT07296484 2026-05-12

CAPTAIN-T2D

Sparrow Pharmaceuticals

Phase 2 Recruiting
1,500 enrolled

ACTH Syndrome, Ectopic, Cushing Syndrome, Diabetes Mellitus, Type 2

NCT03604198 2026-04-21

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

Corcept Therapeutics

Phase 2 Active not recruiting
125 enrolled
Endocrine

ACTH Syndrome, Ectopic, Adrenal Cortex Neoplasms, Cushing Syndrome, Diabetes Mellitus, Type 2, Hypertension, Adrenocortical Carcinoma, Pituitary ACTH Hypersecretion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡